Seroma and Hematoma Rates: MAXIGESIC IV vs. Ketorolac in Breast Cancer Surgery
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age20-70
SponsorSeoul National University Hospital
About this trial
The investigators aim to compare the incidence rates of seroma (fluid collection) and hematoma (blood clot) following breast cancer surgery between the conventional non-steroidal anti-inflammatory drug (NSAID) Ketorolac and MAXIGESIC. The investigators seek to determine the complication rates in patients receiving MAXIGESIC post-surgery, hypothesizing that the higher dosage of ibuprofen in MAXIGESIC compared to Ketorolac will result in lower complication rates.
Eligibility criteria
Qualifiers
Systemic performance status 0-2 according to ECOG criteria
Patients with adequate renal function: serum Cr 1.4 mg/dL or less
Patients with adequate liver function Bilirubin, AST/ALT: 1.5 times or less of the upper limit of normal, Alkaline phosphatase: 1.8 times or less of the upper limit of normal
Patients undergoing total mastectomy with SLNB or ALND (mastectomy and axillary sentinel lymph node dissection)
Disqualifiers
Patients undergoing immediate reconstruction operation
Patients with drug allergies to painkillers and anti-inflammatory drugs
Patients with a physical condition that would interfere with understanding and submitting the consent form
Trial design
Treatments tested in this trial
- Not listed
Trial groups
60 Participants
are grouped into 2 trial groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov